<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975779</url>
  </required_header>
  <id_info>
    <org_study_id>14917A</org_study_id>
    <secondary_id>2012-005648-10</secondary_id>
    <nct_id>NCT01975779</nct_id>
  </id_info>
  <brief_title>Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single- and multiple doses of Lu AE58054 in
      healthy young Japanese men in comparison with Caucasian men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two parts.

      Part A consists of two cohorts (named cohort A1 and A2), which are randomised, double-blind,
      parallel-group, placebo-controlled, single- and multiple dose regimens investigating the
      safety, tolerability, and pharmacokinetics of Lu AE58054 in healthy young men.

      Part B consists of one cohort, B1, which is a randomised, open-label, two-way cross-over,
      single dose investigation of the effect of food on the pharmacokinetics of Lu AE58054 in
      healthy young Japanese men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and frequency of adverse events</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Standard clinical safety assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Adverse event monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the Lu AE58054 plasma concentration-time curve in a dosing interval (AUC0-tau)</measure>
    <time_frame>Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Lu AE58054 plasma concentration-time curve from zero to infinity (AUC0-inf)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) and time of observation (tmax)</measure>
    <time_frame>Day 1 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F), apparent volume of distribution (Vz/F), and elimination halflife (tÂ½)</measure>
    <time_frame>Day 1 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index following multiple dosing of Lu AE58054 (AI)</measure>
    <time_frame>Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Suicidality</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbian Classification Algorithm for Suicide Assessment (C-CASA) definitions for Part A</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A1: Lu AE58054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: Lu AE58054 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1: Lu AE58054</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort A1: Lu AE58054 or placebo</intervention_name>
    <description>One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.</description>
    <arm_group_label>Cohort A1: Lu AE58054 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort A2: Lu AE58054 or placebo</intervention_name>
    <description>One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.</description>
    <arm_group_label>Cohort A2: Lu AE58054 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort B1: Lu AE58054</intervention_name>
    <description>Two single oral doses 60 mg with &gt;=7 days washout.</description>
    <arm_group_label>Cohort B1: Lu AE58054</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese (Japanese passport, four Japanese grandparents, and lives outside
             Japan for less than 5 years) or Caucasian men aged 20 to 45 years with a BMI between
             18 and 25 kg/m2 (extremes included).

        Exclusion Criteria:

          -  The subject is, in the opinion of the investigator, unlikely to comply with the
             clinical study protocol or is unsuitable for any other reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GB001</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

